Significance of the proper acclimatization, use of the acetazolamide and dexamethasone in prevention of acute mountain sickness (AMS) – literature review
DOI:
https://doi.org/10.12775/JEHS.2020.10.02.009Keywords
acute mountain sickness, AMS, acclimatization, acetazolamide, dexamethasoneAbstract
Acute mountain sickness (AMS) is an ilness, that occurs in non-acclimatized individuals after rapid ascent to high altitude, typically above 2,500 metres (8,000 ft). The main causes of the AMS are: reduced air pressure and lower oxygen levels at high altitudes. The early symptoms of AMS are non-specific such as: headache, anorexia, nausea, vomiting, fatigue, dizziness, and sleep disturbance, but not all need to be present at one time. It is very important to recognise the early symptoms of AMS and to start the treatment, because untreated AMS can progress to the life‐threatening: high altitude cerebral edema (HACE) and high altitude pulmonary edema (HAPE). Treatment of AMS consists of stabilization of the patient conditon, descent to lower altitude, oxygen therapy and administering acetazolamide and dexamethasone. The aim of this study was to evaluate the significance of the proper acclimatization, use of the acetazolamide and dexamethasone in prevention of acute mountain sickness (AMS).
Proper acclimatization, use of the acetazolamide and dexamethasone are highly effective in prevention of occurrence and reducing the symptoms of acute mountain sickness (AMS). Pharmacological prophylaxis is not necessary in low-risk situations but should be considered in addition to gradual ascent for use in moderate- to high-risk situations Acetazolamide should be strongly considered in climbers and travelers at moderate or high risk of AMS with ascent to high altitude. Dexamethasone can be used as an alternative in individuals with a history of intolerance of or allergic reaction to acetazolamide. In rare circumstances (eg, military or rescue teams that must ascend rapidly to and perform physical work at >3500 m), consideration can be given to concurrent use of acetazolamide and dexamethasone.
References
Hackett P.H., Roach, R.C. High-altitude illness. N Engl J Med. 2001; 345: 107–114.
Luks A.M., Swenson E.R., Bärtsch P. Acute high-altitude sickness. Eur Respir Rev. 2017 Jan 31;26(143)
Hartman-Ksycińska A., Kluz-Zawadzka J., Lewandowski B. High altitude illness Przegl Epidemiol. 2016;70(3):490-499.
Hackett, P.H., Rennie, D., and Levine, H.D. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976; 2: 1149–1155
Hackett, P.H. and Roach, R.C. High altitude cerebral edema. High Alt Med Biol. 2004; 5: 136–146
Gabry, A.L., Ledoux, X., Mozziconacci, M., and Martin, C. High-altitude pulmonary edema at moderate altitude (<2,400 m; 7,870 feet): a series of 52 patients. Chest. 2003; 123: 49–53
Bloch, K.E., Turk, A.J., Maggiorini, M., Hess, T., Merz, T., Bosch, M.M. et al. Effect of ascent protocol on acute mountain sickness and success at Muztagh Ata, 7546 m. High Alt Med Biol. 2009; 10: 25–32
Beidleman, B.A., Fulco, C.S., Muza, S.R., Rock, P.B., Staab, J.E., Forte, V.A. et al. Effect of six days of staging on physiologic adjustments and acute mountain sickness during ascent to 4300 meters. High Alt Med Biol. 2009; 10: 253–260
Luks, A.M., McIntosh, S.E., Grissom, C.K., Auerbach, P.S., Rodway, G.W., Schoene, R.B. et al. Wilderness Medical Society Practice Guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness Environ Med. 2014; 25: S4–S14
Gertsch, J.H., Basnyat, B., Johnson, E.W., Onopa, J., and Holck, P.S. Randomised, double blind, placebo controlled comparison of Ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. 2004; 328: 797
Grissom, C.K., Roach, R.C., Sarnquist, F.H., and Hackett, P.H. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med. 1992; 116: 461–465
Basnyat, B., Holck, P.S., Pun, M., Halverson, S., Szawarski, P., Gertsch, J. et al. Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness Environ Med. 2019; 30: 3-18.
Johnson T.S., Rock P.B., Fulco C.S. Prevention of acute mountain sickness by dexamethasone. N Engl J Med 1984; 310: 683–686.
Ellsworth A.J., Larson, E.B., and Strickland, D. A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med. 1987; 83: 1024–103
Ellsworth A.J., Meyer, E.F., and Larson, E.B. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med. 1991; 154: 289–293
Maggiorini M., Brunner-La Rocca, H.P., Peth, S., Fischler, M., Bohm, T., Bernheim, A. et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med. 2006; 145: 497–506
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 518
Number of citations: 0